Liquidia to Ask FDA to Remove PH-ILD From Yutrepia Label

Liquidia (LQDA) intends to submit a supplemental new drug application to the FDA for its drug Yutrepia to remove Pulmonary Hypertension with Interstitial Lung Disease (PH-ILD) indication from its label.